Novartis Message Board - Msg: 13687144

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novartis

NVS 122.63

+0.7%

Oct 30 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mark H. Bornfeld who wrote ()	5/11/2000 3:12:00 PM
From: Jack Hartmann	of 296

Novartis CEO: Listing On NYSE To Raise Co's Profile Dow Jones Newswires NEW YORK -- The debut of pharmaceutical concern Novartis AG's (NVS) shares on the New York Stock Exchange Thursday will benefit the company's visibility, said Chief Executive Daniel Vasella. Vasella told CNBC Thursday that Novartis had wanted its shares listed on the largest trading market for 10 years. When asked if he also expects the listing to improve liquidity and acquisition opportunities, Vasella said acquisitions are not the primary objective. He declined to comment on whether Novartis has plans to make a second bid for American Home Products Corp. (AHP). Vasella said Novartis has successfully integrated its most recent acquisitions. Many of them have completed drug development plans or have already filed applications with the Food and Drug Administration, he added. -Kaja Whitehouse; Dow Jones Newswires; 201-938-5393

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next